What is Advanced Oncotherapy?
Advanced Oncotherapy is a pioneering medical technology firm specializing in the development of proton therapy systems designed to improve cancer treatment outcomes. At the core of its innovation is the Linac Image Guided Hadron Technology (LIGHT), a proprietary proton accelerator that significantly reduces the physical footprint and capital expenditure required for traditional proton therapy installations. By miniaturizing the technology while enhancing beam precision, the company enables healthcare providers to offer high-quality, targeted radiation therapy with fewer side effects. The firm operates at the intersection of high-energy physics and clinical oncology, positioning itself as a critical provider for hospitals seeking to modernize their radiotherapy capabilities without the prohibitive costs associated with legacy systems.
How much funding has Advanced Oncotherapy raised?
Advanced Oncotherapy has raised a total of $23.3M across 5 funding rounds:
Multiple Rounds
$13.3M
Share Placement
$10M
Debt (2017): $3.7M with participation from Blackfinch Investments
Debt (2017): $2.6M led by Blackfinch Investment.
Debt (2017): $1.9M supported by Blackfinch Investment.
Debt (2017): $5.1M, investors not publicly disclosed
Share Placement (2020): $10M backed by SI Capital Ltd
Key Investors in Advanced Oncotherapy
Blackfinch Investments
An investment firm focused on providing capital across various sectors, including technology and healthcare, to support long-term growth and innovation.
SI Capital Ltd
A financial services firm specializing in equity capital markets and strategic investment advisory for growth-stage companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Advanced Oncotherapy?
With the recent infusion of capital, Advanced Oncotherapy is well-positioned to accelerate the commercial deployment of its LIGHT system. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding clinical partnerships to integrate its compact proton accelerators into global healthcare networks. As the company moves beyond the development phase, the emphasis will remain on maintaining its competitive edge in the proton therapy market by refining its electronic beam control and pursuing further technological optimizations. Investors are closely monitoring the firm's ability to translate its technical milestones into widespread clinical adoption, which remains the primary catalyst for long-term value creation in the oncology sector.
See full Advanced Oncotherapy company page
